Status:
UNKNOWN
PCSP Implementation Study
Lead Sponsor:
Istituto Giannina Gaslini
Conditions:
Survivorship
Late Effect
Eligibility:
All Genders
5+ years
Brief Summary
This study protocol describes the design and methods of the PanCareSurPass (PCSP) multi-country implementation study of the Survivorship Passport v2.0 (short: PCSP implementation study), which is part...
Eligibility Criteria
Inclusion
- being diagnosed with cancer before the age of 18 years;
- have completed the planned treatment protocol;
- being still in continuous, complete remission at least five years from primary cancer diagnosis (≥5 years survivorship);
- being in follow-up care at one of the institutions participating in the study;
- have signed informed consent/assent to the study according to local legislation.
Exclusion
- currently in treatment for secondary malignancy or relapse of primary malignancy;
- have already received previous versions of the SurPass (v1.0 - 1.2).
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2025
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT05982587
Start Date
August 1 2023
End Date
February 28 2025
Last Update
August 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Giannina Gaslini
Genoa, Italy, 16147